Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Ovarian Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma in Situ 1

Interventions

Paclitaxel 77pembrolizumab 65Carboplatin 57Bevacizumab 57Specimen Handling 49Magnetic Resonance Spectroscopy 40Cisplatin 35olaparib 31Gemcitabine 27liposomal doxorubicin 25Biopsy 22Taxes 19Cyclophosphamide 18Topotecan 17Nivolumab 17Doxorubicin 16Immunoglobulin G 15niraparib 14Letrozole 14Disulfides 14lenvatinib 13fludarabine 13Surveys and Questionnaires 12Drug Therapy 12Radiotherapy 11Platinum 11atezolizumab 10abemaciclib 10durvalumab 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Indomethacin × Gynecologic × 90 days × Clear all
NCT01719926 2026-06-04

PIFA

UMC Utrecht

Phase 1 Completed
13 enrolled
GastrointestinalGynecologic

Esophageal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡